CHINA'S FAST-TRACK
ONCOLOGY TRIAL ECOSYSTEM
China has quietly become one of the world's most important oncology trial destinations โ driven by regulatory reform, large patient populations, specialist hospitals, domestic biotech, and a genuine willingness to run China-first studies. A patient guide to what this means and how to access it.
analyticsAt a Glance
- check_circleChina runs more oncology clinical trials than any country outside the US โ covering CAR-T, bispecific antibodies, ADCs, targeted drugs, immunotherapy combinations, and gene therapy.
- check_circleNMPA regulatory reform since 2017 has created accelerated pathways for oncology drugs โ with some therapies approved in China before or alongside global regulatory decisions.
- check_circleLarge patient populations and concentrated expertise at national cancer centres allow trials to recruit faster โ giving patients earlier access to experimental therapies.
- check_circleFor cancers with high Asian prevalence โ gastric, liver, lung, nasopharyngeal โ China has the deepest trial pipeline in the world.
Why China Has Become a Leading Trial Destination
China's clinical trial leadership is the result of five reinforcing factors โ not a single policy change or coincidence.
NMPA Regulatory Reform
China's National Medical Products Administration implemented major regulatory reforms from 2017 โ including priority review pathways for oncology drugs, accelerated breakthrough designation, and conditional approval mechanisms. These reforms have shortened approval timelines significantly and created structured pathways for hospital-based investigational studies.
Large Patient Populations and Trial Speed
China's large population and high cancer incidence โ particularly for gastric, liver, lung, nasopharyngeal, and oesophageal cancers โ means clinical trials can recruit patients faster than in most other countries. Faster recruitment means results emerge sooner and sponsors run China-first or China-included studies as a strategic priority.
Domestic Biotech and Sponsor Investment
China has developed a substantial domestic biotech sector producing innovative drugs โ not just copies. Companies including BeiGene, Zymeworks, ABL Bio partners, and dozens of others are running China-originating studies that advance to global registration. Global sponsors also increasingly include China in multi-country programmes from the early phases.
Specialist Cancer Hospital Infrastructure
National cancer centres โ CAMS Cancer Hospital Beijing, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center โ combine clinical volume, specialist teams, and dedicated research infrastructure. Hospital-based research pathways allow trials to run alongside standard clinical care in a way that accelerates both recruitment and results.
Key Trial Categories and What They Mean for Patients
China's oncology trial pipeline spans a wide range of therapy types. The categories most relevant to international patients include:
| Therapy Category | Trial Activity in China | Who It May Benefit |
|---|---|---|
| CAR-T Cell Therapy | 600+ registered studies โ CD19, BCMA, dual-target, allogeneic, solid tumours | Relapsed/refractory lymphoma, leukaemia, myeloma after prior lines |
| Bispecific Antibodies | Active Phase I/II/III studies โ CD3xCD19, CD3xBCMA, CD3xEGFR and others | Blood cancers and selected solid tumours; prior CAR-T or BMT patients |
| Antibody-Drug Conjugates (ADCs) | Multiple Phase II/III studies โ HER2, TROP2, Claudin 18.2, EGFR-targeted | Breast, lung, gastric, colorectal, and urothelial cancers with relevant biomarkers |
| Targeted Therapy (Next-Gen) | EGFR 4th-gen, ALK 3rd-gen, KRAS G12C, MET amplification | NSCLC, CRC, gastric cancer with specific mutations after prior TKI therapy |
| Immunotherapy Combinations | PD-1/PD-L1 + chemotherapy, TKI, radiotherapy, bispecific combinations | Multiple solid tumour types โ particularly GI, lung, liver, and head and neck |
| Gene Therapy | Phase I/II for thalassaemia, sickle cell, haemophilia, and selected rare cancers | Inherited blood disorders; some rare cancer types without approved treatment |
How to Access a Clinical Trial in China
Finding and accessing a relevant trial in China involves more than a database search โ clinical suitability and practical feasibility both require structured review.
- 1
Assemble Complete Medical Records
Pathology with molecular profiling, all imaging, complete treatment history, current blood tests, and any prior trial records. The completeness of records directly determines whether a meaningful eligibility assessment is possible.
- 2
Identify Clinically Relevant Trials
Match diagnosis, biomarkers, and prior treatment lines against active trial protocols. CancerFax reviews the medical picture and identifies which trial categories are realistically worth exploring versus which are unlikely to fit.
- 3
Submit for Eligibility Screening
Reports are submitted to the relevant hospital or trial team for formal eligibility review. Initial screening typically takes 1-3 weeks and may require additional tests.
- 4
Confirm Practical Feasibility
Travel readiness, support person availability, disease stability for the transit and waiting period, and financial planning for the full cost of stay โ not just trial drug cost.
- 5
Enrol, Travel, and Begin
Once eligibility is confirmed and logistics are planned, CancerFax coordinates admission, interpretation, hospital communication, and follow-up with the home oncology team.
Key Numbers
- 600+Registered CAR-T Trials in ChinaMore than any other country. Covers blood cancers and emerging solid tumour programmes.
- 2017Year of NMPA Regulatory ReformAccelerated pathways for breakthrough therapies โ reducing approval timelines and creating hospital-based research frameworks.
- 4 of 5Top Gastric Cancer Trial Sites Are in ChinaChina's high gastric cancer incidence makes it the most active trial destination for this cancer globally.
- 3-5 yrsPotential Early Access via China Trials vs Standard ApprovalFor some therapies, trial access in China precedes global market approval by several years.
Frequently Asked Questions
About Clinical Trials in China
Can international patients join clinical trials in China?
Yes, in principle. Many China-based trials include international patients โ particularly those run at major national cancer centres with international patient services. Eligibility depends on the specific study protocol, and practical requirements include willingness to stay in China for the trial duration, fitness to travel, and adequate disease stability during the enrolment window.
Is clinical trial treatment free in China?
The experimental drug or therapy is often provided free of charge in a clinical trial. However, diagnostic tests, hospital stay, supportive care, travel, accommodation, and interpreter services are separate costs. For a CAR-T trial, the cell therapy product may be free but the overall stay can still cost USD 20,000-50,000 in total. Always clarify the full cost picture before committing.
How do I know if a trial in China is legitimate?
Legitimate trials in China are registered on ClinicalTrials.gov or China's national trial registry (chictr.org.cn), run at established hospital institutions, and have defined eligibility criteria and ethics approval. CancerFax evaluates pathway credibility as part of the case review โ patients should not self-refer to trial listings without clinical review of suitability and institutional quality.
What happens if I am not eligible for the trial?
If a specific trial pathway is not suitable, CancerFax reviews other relevant options โ approved product pathways, alternative trials, or treatment programmes in other countries. The aim is always a medically appropriate next step rather than pushing a single pathway.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could a Clinical Trial in China Be the Right Next Step?
Share your medical reports and treatment history โ our team will identify whether an active trial in China matches your diagnosis, biomarkers, and prior treatment, and arrange eligibility screening before you make any travel decision.
This information is for patient education and navigation support only. Trial eligibility is determined by the treating team, not by CancerFax.